These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 26653735)

  • 1. Development of a selective matrix metalloproteinase 13 (MMP-13) inhibitor for the treatment of Osteoarthritis.
    Bendele AM; Neelagiri M; Neelagiri V; Sucholeiki I
    Eur J Med Chem; 2021 Nov; 224():113666. PubMed ID: 34245949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin 36 receptor-inducible matrix metalloproteinase 13 mediates intestinal fibrosis.
    Koop K; Enderle K; Hillmann M; Ruspeckhofer L; Vieth M; Sturm G; Trajanoski Z; Kühl AA; Atreya R; Leppkes M; Baum P; Roy J; Martin A; Neurath MF; Neufert C
    Front Immunol; 2023; 14():1163198. PubMed ID: 37207229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule inhibitors of osteoarthritis: Current development and future perspective.
    Liu D; Li X; Zhang L; Hu B; Hu S; Zhang X; Hu J
    Front Physiol; 2023; 14():1156913. PubMed ID: 37089415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of MMP-13 as a Promising Target for the Treatment of Osteoarthritis.
    Hu Q; Ecker M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zinc and Cadmium in the Aetiology and Pathogenesis of Osteoarthritis and Rheumatoid Arthritis.
    Frangos T; Maret W
    Nutrients; 2020 Dec; 13(1):. PubMed ID: 33375344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix Metalloproteinase 13 Inhibitors for Modulation of Osteoclastogenesis: Enhancement of Solubility and Stability.
    Knapinska AM; Singh C; Drotleff G; Blanco D; Chai C; Schwab J; Herd A; Fields GB
    ChemMedChem; 2021 Apr; 16(7):1133-1142. PubMed ID: 33331147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma.
    Fields GB
    Cells; 2019 Aug; 8(9):. PubMed ID: 31461880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of MMPs and ADAM/ADAMTS.
    Malemud CJ
    Biochem Pharmacol; 2019 Jul; 165():33-40. PubMed ID: 30826330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study.
    Fuerst R; Yong Choi J; Knapinska AM; Smith L; Cameron MD; Ruiz C; Fields GB; Roush WR
    Bioorg Med Chem; 2018 Oct; 26(18):4984-4995. PubMed ID: 30249495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dehydrogenative reagent-free annulation of alkenes with diols for the synthesis of saturated O-heterocycles.
    Cai CY; Xu HC
    Nat Commun; 2018 Sep; 9(1):3551. PubMed ID: 30177691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
    Schnute ME; O'Brien PM; Nahra J; Morris M; Howard Roark W; Hanau CE; Ruminski PG; Scholten JA; Fletcher TR; Hamper BC; Carroll JN; Patt WC; Shieh HS; Collins B; Pavlovsky AG; Palmquist KE; Aston KW; Hitchcock J; Rogers MD; McDonald J; Johnson AR; Munie GE; Wittwer AJ; Man CF; Settle SL; Nemirovskiy O; Vickery LE; Agawal A; Dyer RD; Sunyer T
    Bioorg Med Chem Lett; 2010 Jan; 20(2):576-80. PubMed ID: 20005097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.
    Nara H; Sato K; Kaieda A; Oki H; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    Bioorg Med Chem; 2016 Dec; 24(23):6149-6165. PubMed ID: 27825552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Research Advances in Selective Matrix Metalloproteinase-13 Inhibitors as Anti-Osteoarthritis Agents.
    Xie XW; Wan RZ; Liu ZP
    ChemMedChem; 2017 Aug; 12(15):1157-1168. PubMed ID: 28722301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Zinc-Binding Inhibitors of MMP-13: GRID-Based Approaches to Rationalize the Binding Process.
    Di Pizio A; Agamennone M; Tortorella P
    Curr Top Med Chem; 2016; 16(4):449-59. PubMed ID: 26268339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials of a stromelysin inhibitor. Osteoarthritis, matrix metalloproteinase inhibition, cartilage loss, surrogate markers, and clinical implications.
    Leff RL
    Ann N Y Acad Sci; 1999 Jun; 878():201-7. PubMed ID: 10415731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.
    Ruminski PG; Massa M; Strohbach J; Hanau CE; Schmidt M; Scholten JA; Fletcher TR; Hamper BC; Carroll JN; Shieh HS; Caspers N; Collins B; Grapperhaus M; Palmquist KE; Collins J; Baldus JE; Hitchcock J; Kleine HP; Rogers MD; McDonald J; Munie GE; Messing DM; Portolan S; Whiteley LO; Sunyer T; Schnute ME
    J Med Chem; 2016 Jan; 59(1):313-27. PubMed ID: 26653735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.
    Nara H; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    J Med Chem; 2014 Nov; 57(21):8886-902. PubMed ID: 25264600
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.